- Home
- MDXG vs INBX Comparison
MDXG vs INBX Comparison
Compare MDXG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDXG | INBX |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.2M | 999.7M |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | MDXG | INBX |
|---|---|---|
| Price | $3.58 | $109.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $9.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.9M | 586.3K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,630,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.99 | ★ 550.00 |
| 52 Week Low | $3.03 | $12.80 |
| 52 Week High | $7.99 | $155.29 |
Technical Indicators
Market Signals| Indicator | MDXG | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 50.41 |
| Support Level | $3.11 | $69.30 |
| Resistance Level | $7.39 | $155.29 |
| Average True Range (ATR) | 0.16 | 13.20 |
| MACD | 0.04 | -3.55 |
| Stochastic Oscillator | 78.01 | 23.22 |
Price Performance
Historical ComparisonAbout MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.